Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Business Wire
- Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance -- First program member is Segal Trials, a preferred provider for leading pharmaceutical companies globally -- Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of patients - TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its first strategic partnership agreement (“SPA”) with Segal Trials in furtherance of Cybin’s multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”).Segal T
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin to Transfer U.S. Stock Exchange Listing to NasdaqBusiness Wire
- KILL Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]Yahoo! Finance
- Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]Yahoo! Finance
- Cybin to Transfer U.S. Stock Exchange Listing to NasdaqBusiness Wire
- Cybin (OTCMKTS:CYBN) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
CYBN
Earnings
- 11/14/25 - Miss
CYBN
Sec Filings
- 12/19/25 - Form F-X
- 12/19/25 - Form F-10
- 12/18/25 - Form 6-K
- CYBN's page on the SEC website